Mogamulizumab with low-dose skin radiation for lymphoma skin disease
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests mogamulizumab together with low-dose total skin electron beam radiation to treat mycosis fungoides or Sézary syndrome, two types of skin lymphoma. It may help shrink skin disease and control symptoms by combining an immune-targeting medicine with skin-focused radiation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- Your disease is mycosis fungoides (MF) or Sézary syndrome (SS) in stage IB, II, III, or IV (not stage IA).
- You’ve had at least one prior standard treatment for your skin lymphoma.
- If you had low-dose total skin radiation (LD-TSEBT) before, it must be more than 3 months ago—and you can’t have had progression or had to stop due to side effects.
- Enough blood, liver, and kidney function based on lab tests done before starting.
- You can’t have certain situations, like active infections (like herpes), HIV, hepatitis B/C, pregnancy or breastfeeding, or disease in the brain/spinal cord.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests how brentuximab vedotin should be dosed for people with mycosis fungoides or Sezary syndrome (skin T-cell lymphoma), and also for lymphomatoid papulosis. It may help improve how well the treatment works while tracking side effects.
This Phase 2 trial tests whether a combination of photopheresis and the drug mogamulizumab can improve outcomes in adults with advanced mycosis fungoides or Sézary syndrome, which are types of skin T-cell lymphoma. It may help by targeting lymphoma cells in the skin and immune system.
This Phase 2 trial studies whether giving very low-dose total-skin electron beam radiation at the same time as brentuximab vedotin can control mycosis fungoides (a lymphoma that affects the skin). It’s for people whose disease has returned or hasn’t responded to prior treatment, especially if the tumor marker CD30 is present.
This trial tests a low-dose radiation treatment to the skin for early-stage mycosis fungoides, a type of lymphoma that affects the skin. The goal is to see if this treatment can help eliminate the cancer cells.
This study looks for “predictive” and “prognostic” biomarkers—measurable signs in blood or tissue—to help predict how mycosis fungoides or Sézary syndrome will behave and how patients may respond to care. It may help doctors better understand outcomes for people with these skin lymphomas.
This early-stage study tests whether a cancer-killing cream (imiquimod) combined with targeted local radiation can shrink and control mycosis fungoides skin lesions. It may help people whose skin lymphoma has not responded to at least one prior standard treatment.
Hear when a new Sezary Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.